INN Active Substances:
Composition of the preparation:
1 ml solution contains:
Active ingredient: 50 mg nandrolone decanoate, 100 mg or 200 mg
Ingredients: Benzyl alcohol, benzil benzoate, peach.
Description of preparation:
Transparent oily solution, color from light yellow to yellow with characteristic odor.
Injectable oily solution
Pharmacotherapeutic group and ATC code
Anabolic steroid, A14A B01.
The synthetic derivative of testosterone with reduced androgenic and anabolic increased. The anabolic effect is manifested by the activation of regenerative processes in the epithelium (skin and glandular), bone and muscle as a result of stimulation of protein synthesis and cellular structural components. Increases absorption capacity of amino acids in the small intestine (the background diet rich in protein), leading to a positive nitrogen balance. Stimulates the synthesis of erythropoietin and activates anabolic processes in the bone marrow, which co-administration of iron preparations is manifested by anti-anemia action. Inhibits endogenous gonadotropin and testosterone. In high doses inhibit spermatogenesis. Can stop growth and sexual development of children.
Disrupts the synthesis of blood coagulation factors dependent plasma vitamin K (II, VII, IX, X) in the liver, plasma lipid profile changes (increased VLDL and reduced HDL concentration) increases the reabsorption of sodium and water in the kidneys, contributing to the development of peripheral edema . These effects disappear after cessation of administration.
After an intramuscular dose of 100 mg the peak plasma concentration is achieved after 1-3 weeks. Subject biotransformation in the liver to form 17-ketosteroizilor. It is predominantly eliminated in the urine (90%) and 6% - feces.
Treatment of anemia in the renal (increased hemoglobin and cell mass), diabetic retinopathy, miodistrofia, Werding-Hoffmann spinal amyotrophy breast cancer (adjuvant), glomerulonephritis, extensive burns, osteoporosis.
Dosage and method of administration:
Deep intramuscular injection.
In anemia (iron preparations while) - 100-200 mg (females - 50-100 mg) 1 time per week; to stimulate anabolic processes - 50-200 mg (women - 50-100 mg) 1 time in 1-4 weeks; children 2 to 13 years - 0.4 mg / kg every 3-4 weeks 1. The duration of the treatment (at an interval of 1-4 weeks between injections) - up to 12 weeks, repeated cure - more than eight weeks after the last administration of the preparation. Treatment is carried out in the background of a diet rich in protein.
Women - virilization symptoms, inhibition of ovarian function, menstrual disorders, hypercalcemia.
Men: in prepubertal - virilization symptoms, skin hyperpigmentation idiopathic withholding or stopping the growth (calcification of epiphyseal growth zones tubular bones); during postpubertal - bladder irritation, gynecomastia, priapism; in the elderly - hypertrophy and / or prostatic carcinoma.
For men and women - the progression of atherosclerosis, peripheral edema, impaired liver function with jaundice, changes in blood count, bone pain sockets, hypercoagulation prone to bleeding.
Hypersensitivity to the drug, prostate cancer, breast cancer in men, breast carcinoma in women with hypercalcemia, CPI, severe atherosclerosis, nephrotic syndrome, acute and chronic liver disease, including alcoholic nephritis, pregnancy, lactation.
Cases of overdose have not been reported.
Warnings and special precautions for use:
The first signs of virilization of patients (deepening of the voice, hirsutism, acne) administration must be stopped to avoid irreversible changes. Suppression may occur plasma coagulation factors II, VII, IX and X and prothrombin time increased. A systematic control the lipidemic and cholesterol. Use should be made of a specialist pediatric experience to avoid premature epiphyseal bone calcification.
Interactions with other drugs:
Glucocorticoids, mineralocorticoids, corticotropin preparations containing sodium and sodium-rich foods enhances fluid retention in the body, increasing the risk of developing edema, acne eruptions intensify. The increased action of antiplatelet, anticoagulant, antidiabetic peroral insulin and decreases the action of somatotropin and its derivatives.
Injectable oily solution 20% of 1 ml in ampoules.
Store in a dry place protected from light, at a temperature of 15-25 ° C.
Keep out of the reach and sight of children.
5 years. Do not use after the expiration date indicated on the packaging.